STADA Group takes a leading position in the third Barmer GEK discount agreement round

  • 9/10/2012

Sales companies secure a total of 19 awards
Bad Vilbel, September 10, 2012 – The STADA Group’s sales companies have taken a leading position in the third tender for discount agreements with Barmer GEK, the largest public health insurance organization in Germany. They were able to secure twelve exclusive and seven multiple awards. The total tender volume came to approximately EUR 382 million according to the insurance. The contracts take effect in November 2012 and apply for 8.7 million insured persons.
“With this success, the STADA Group has once again proven its strong position and efficiency in the challenging environment of German discount agreements”, says Hartmut Retzlaff, Chairman of the Executive Board. “With a view to the successful results of recent discount agreement rounds, we are confident that we will be able to further expand our share of the German generics market.”
Of the active pharmaceutical ingredients awarded to companies in the STADA Group, ten are attributable to ALIUD PHARMA, eight to STADApharm and one to a consortium bid from STADApharm and another manufacturer. One active pharmaceutical ingredient is shared by STADApharm and ALIUD PHARMA in a multiple award. Overall, the STADA Group was thereby awarded 18 active ingredients including ibuprofen and dorzolamide.
About STADA Arzneimittel AG:
STADApharm GmbH and ALIUD PHARMA GmbH are sales companies of STADA Arzneimittel AG. The Group is present in over 30 countries and has, among other things, production facilities in Germany, Russia, Serbia, Vietnam and China. In 2011, STADA Arzneimittel AG generated EUR 1.7 billion in sales and had 7,867 employees worldwide as of June 30, 2012. In addition to generics, STADA focuses on known branded products such as Grippostad, Mobilat and Ladival.
For more information, please contact:
STADA Arzneimittel AG
Corporate Communications
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506